Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as an Advanced provider by MediFind in the treatment of Metastatic Insulinoma. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Cameron has had a long and distinguished career in alimentary tract diseases and specifically in pancreatic cancer. He has won worldwide acclaim for mastering the Whipple procedure. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30 percent. He has worked to lower that to 1 percent to 2 percent at Johns Hopkins. He has operated on more patients with pancreatic cancer and done more Whipple resections than any other surgeon in the world. In addition to maintaining a busy practice that focuses mainly on pancreatic surgery, he has been a leader in the surgical profession, serving as president of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Southern Surgical Association, Society of Clinical Surgery, Society of Surgical Chairmen, Halsted Society and American Surgical Association. He served as chief of surgery for The Johns Hopkins Hospital for nineteen years. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958, and his medical degree from The Johns Hopkins University School of Medicine in 1962. All of his training in General and Thoracic Surgery was obtained at The Johns Hopkins Hospital. Dr. Cameron is rated as an Advanced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

David J. Hackam, M.D., Ph.D., is the Garrett Family Professor of Pediatric Surgery at The Johns Hopkins University, and Pediatric Surgeon-in-Chief and co-Director of the Johns Hopkins Children’s Center. Dr. Hackam’s clinical practice focuses on complex neonatal surgery. As pediatric surgeon in chief and co-director of the Childrens Center, Dr. Hackam oversees all perioperative clinical operations that involve children, with a strong emphasis on quality and safety, programmatic growth, and system alignment. Dr. Hackam's research is focused on unraveling the mechanisms of necrotizing enterocolitis, which is the leading cause of death in premature infants from gastrointestinal disease. His work has identified a series of novel pathways that, in response to the abnormal microflora that characterizes the premature intestine, leads to intestinal mucosal barrier breakdown, bacterial translocation, mesenteric vasoconstriction, and NEC. In seeking to translate these findings to clinical studies, we have developed a family of molecules that can prevent NEC development, and which have in part been licensed for clinical development. In additional work, Hackam has developed a prototype artificial intestine, derived from patient-specific intestine stem cells, which we have implanted into pre-clinical models, for the treatment of short bowel syndrome, a devastating complication of NEC. Finally, using single-cell RNA-seq and cell tracking technology, Hackam has worked towards understanding and treating NEC-associated brain injury, a major complication of NEC, and has engineered nanoparticle-packaged molecules that can cross the blood-brain barrier, and reverse the processes that lead to this disease. These studies are funded by three ro1s, a T32, a MIRA (a maximizing investigators’ research award) and 3 industry grants from companies with an interest in NEC treatment and prevention. Dr. Hackam seeks to work with industry partners, as well as nurses, doctors, and families of patients around the country, in order to develop novel regimens to safely and effectively deliver appropriate nutrition to the most vulnerable infants, who are at risk for the development of intestinal disease. Dr. Hackam is rated as an Advanced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Necrotizing Enterocolitis, Necrosis, Short Bowel Syndrome, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Jin He, M.D., Ph.D., is a professor of surgery at the Johns Hopkins University School of Medicine and is the Division Chief of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology. Dr. He specializes in diseases and tumors of the pancreas, liver, bile duct, and gallbladder. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure. Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by an ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins. Dr. He is the John Cameron Professor of Alimentary Tract Diseases. Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees, including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology. Dr. He is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Sandy Kotiah is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Kotiah is rated as an Advanced provider by MediFind in the treatment of Metastatic Insulinoma. Her top areas of expertise are Neuroendocrine Tumor, Paget Disease of the Breast, Anemia, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Kotiah is currently accepting new patients.

Paul Colombani is a General Surgeon in Baltimore, Maryland. Dr. Colombani is rated as an Advanced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Pectus Excavatum, Metastatic Insulinoma, Pancreatoblastoma, Hepato-Pancreato-Biliary Surgery, and Kidney Transplant.

Petr Hausner is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Hausner is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, and Anal Cancer. Dr. Hausner is currently accepting new patients.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Gurdeep Chhabra is a Hematologist Oncology specialist and a Hematologist in California, Maryland. Dr. Chhabra is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Small Cell Lung Cancer (SCLC). Dr. Chhabra is currently accepting new patients.

Sadaf Taimur is a Hematologist Oncology specialist and a Hematologist in Brandywine, Maryland. Dr. Taimur is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Pulmonary Embolism. Dr. Taimur is currently accepting new patients.

Aditya Chopra is a primary care provider, practicing in Internal Medicine in Annapolis, Maryland. Dr. Chopra is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Heart Murmurs, Dementia, Empyema, and Sinusitis. Dr. Chopra is currently accepting new patients.

Nouman Asif is a Hematologist Oncology specialist and a Hematologist in Frederick, Maryland. Dr. Asif is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Anemia, and Thrombocytopenia. Dr. Asif is currently accepting new patients.

Jun Sun is a Hematologist Oncology specialist and a Hematologist in Brandywine, Maryland. Dr. Sun is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Pulmonary Embolism. Dr. Sun is currently accepting new patients.

Pamela Simpson is a Hematologist Oncology specialist and a Hematologist in Easton, Maryland. Dr. Simpson is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. Her top areas of expertise are Paget Disease of the Breast, Lymphomatoid Papulosis, Breast Cancer, and Anaplastic Large Cell Lymphoma. Dr. Simpson is currently accepting new patients.

Pallavi Kumar is a Hematologist Oncology specialist and an Oncologist in Randallstown, Maryland. Dr. Kumar is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. Her top areas of expertise are Endometrial Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Familial Pancreatic Cancer. Dr. Kumar is currently accepting new patients.

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

Rabindra Paul is a Hematologist and an Oncologist in Snow Hill, Maryland. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Inflammatory Breast Cancer, Colorectal Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Sajjad Haider is a Hematologist Oncology specialist and a Hematologist in Westminster, Maryland. Dr. Haider is rated as an Experienced provider by MediFind in the treatment of Metastatic Insulinoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Haider is currently accepting new patients.